CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
6.82BCNY1.02B · vs all stocks (USD)
Revenue (TTM)
373.09MCNY55.65M · vs all stocks (USD)
Profit Margin
-96.68%52-Week Change
-25.80%vs all stocks
Market Capitalization
6.82BCNY1.02B · vs all stocks (USD)
Enterprise Value
5.38BCNY803.17M · vs all stocks (USD)
Forward P/E
6.31xPrice to Sales (TTM)
18.10xPrice to Book (MRQ)
1.47xEnterprise to Revenue
14.43xEnterprise to EBITDA
-39.33xGross Margin
26.29%Profit Margin
-96.68%Operating Margin
-93.66%Return on Assets (TTM)
-2.73%Return on Equity (TTM)
-9.20%Revenue (TTM)
373.09MCNY55.65M · vs all stocks (USD)
Revenue per Share (TTM)
0.1780CNYUpdated Sep 19, 2026Quarterly Revenue Growth
-29.90%Gross Profit (TTM)
174.54MCNY26.03M · vs all stocks (USD)
EBITDA (TTM)
-136.92MCNY-20.42M · vs all stocks (USD)
Net Income (TTM)
-360.69MCNY-53.80M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-29.93%Operating Cash Flow (TTM)
-75.37MCNY-11.24M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-232.81MCNY-34.73M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
-63.12MCNYFY2025 · Dec 31, 2025Revenue
396.81MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
173.98MCNYFY2025 · Dec 31, 2025Gross Profit
222.83MCNYFY2025 · Dec 31, 2025Operating Income
-173.53MCNY-25.88M · vs all stocks (USD)
Pre-tax Income
-420.42MCNYFY2025 · Dec 31, 2025Income Tax Expense
1.50MCNYFY2025 · Dec 31, 2025Net Income
-421.93MCNYFY2025 · Dec 31, 2025EBIT
-418.11MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-94.43MCNYFY2025 · Dec 31, 2025Research & Development
82.28MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
132.91MCNYFY2025 · Dec 31, 2025Other Operating Expenses
15.13MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
17.22MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.31MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.1633CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.1633CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
2.12BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
2.12BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-421.93MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
76.51MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-340.71MCNYFY2025 · Dec 31, 2025Free Cash Flow
-576.12MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.76BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-421.93MCNYFY2025 · Dec 31, 2025Other Non-cash Items
48.27MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-6.66MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
39.60MCNYFY2025 · Dec 31, 2025Capital Expenditures
-235.41MCNYFY2025 · Dec 31, 2025Purchase of Investments
-460.00MCNYFY2025 · Dec 31, 2025Sale of Investments
10.04MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-685.38MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
114.80MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-2.37MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-1.48MCNYFY2025 · Dec 31, 2025Other Financing Charges
-131.75MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-20.80MCNYFY2025 · Dec 31, 2025Shares Outstanding
2.10BSharesUpdated Sep 19, 2026Float Shares
1.33BSharesUpdated Sep 19, 2026% Held by Insiders
48.51%vs all stocks
% Held by Institutions
0.99%vs all stocks
Total Cash (MRQ)
1.35BCNY201.07M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.6460CNYUpdated Sep 19, 2026Total Debt (MRQ)
131.32MCNY19.59M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0292xCurrent Ratio (MRQ)
15.89xBook Value per Share (MRQ)
2.19CNYUpdated Sep 19, 2026Total Assets
4.87BCNY726.71M · vs all stocks (USD)
Total Current Assets
2.57BCNYFY2025 · Dec 31, 2025Total Liabilities
299.50MCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.30BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
143.70MCNYFY2025 · Dec 31, 2025Total Current Liabilities
155.80MCNYFY2025 · Dec 31, 2025Cash
1.80BCNYFY2025 · Dec 31, 2025Cash Equivalents
1.21MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.81BCNYFY2025 · Dec 31, 2025Other Short-term Investments
10.08MCNYFY2025 · Dec 31, 2025Accounts Receivable
234.33MCNYFY2025 · Dec 31, 2025Inventory
147.57MCNYFY2025 · Dec 31, 2025Accounts Payable
76.18MCNYFY2025 · Dec 31, 2025Short-term Debt
8.25MCNYFY2025 · Dec 31, 2025Other Current Liabilities
254.13KCNYFY2025 · Dec 31, 2025Long-term Debt
126.53MCNYFY2025 · Dec 31, 2025Common Stock (Book)
801.23MCNYFY2025 · Dec 31, 2025Retained Earnings
3.57BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
4.57BCNY682.04M · vs all stocks (USD)
52-Week Low
2.75CNYUpdated Sep 19, 202652-Week High
4.73CNYUpdated Sep 19, 202652-Week Change
-25.80%vs all stocks
50-Day MA
3.37CNYUpdated Sep 19, 2026200-Day MA
3.57CNYUpdated Sep 19, 2026Avg 10-Day Volume
93.37MSharesUpdated Sep 19, 2026Avg 30-Day Volume
63.01MSharesUpdated Sep 19, 2026Diluted EPS (TTM)
-0.1700CNYUpdated Sep 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 18.10Revenue Growth YoY: -0.30
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Shantou Institute of Ultrasonic Instruments Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangyuyuan Chinese Herbal Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
MoonLake Immunotherapeutics
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tianjin Tianyao Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Blue Jet Healthcare Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Haohai Biological Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Savara Inc.
Tier 1ProductionApproval-Gated PipelineRule
0009K0
Tier 1ProductionApproval-Gated PipelineRuleRisk
Monte Rosa Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sunflower Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule